EODData

MEMBERSHIP REGISTER LOG IN

FRA, 722: ANTENGENE CORP. DL-0001

05 Nov 2025
LAST:

0.5400

CHANGE:
 0.01		OPEN:
0.5400		HIGH:
0.5400		ASK:
0.0000		VOLUME:
103
CHG(%):
1.89		PREV:
0.5300		LOW:
0.5400		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 250.54000.54000.54000.5400103
04 Nov 250.53000.53000.53000.5300103
31 Oct 250.54000.54000.54000.5400103
30 Oct 250.52000.52000.52000.5200103
29 Oct 250.52500.52500.52500.5250103
28 Oct 250.51000.51000.51000.5100103
27 Oct 250.54000.54000.54000.5400103
24 Oct 250.51000.51000.51000.5100103
23 Oct 250.48600.48600.48600.4860103
22 Oct 250.54000.54000.54000.5400103

COMPANY PROFILE

Name:ANTENGENE CORP. DL-0001
About:Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company's pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
Sector:Healthcare
Industry:Biotechnology
Address:Zhongshan SOHO Plaza, Shanghai, China, 200051
Website:https://www.antengene.com
ISIN:KYG039571008

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.04 
Price to Sales:4.02 
Price to Book:0.43 
Profit Margin:-2.71 
Operating Margin:-2.13 
Return on Assets:-0.13 
Return on Equity:-0.26 
Revenue:10.28M 
Shares:611.13M 
Market Cap:330.01M 

TECHNICAL INDICATORS

MA5:0.531.7%
MA10:0.523.0%
MA20:0.575.3%
MA50:0.6622.1%
MA100:0.552.4%
MA200:0.4228.8%
STO9:100.00 
STO14:60.67
RSI14:44.40
WPR14:-39.33
MTM14:-0.04
ROC14:-0.06 
ATR:0.02 
Week High:0.540.0%
Week Low:0.523.8%
Month High:0.7232.4%
Month Low:0.4928.8%
Year High:0.8557.4%
Year Low:0.051,100.0%
Volatility:16.38